
Gilead Sciences, Inc.
GILDHealthcare|Drug Manufacturers - General|US
$166.89
-0.68 (-0.41%)
DCF Value
$137.19
Cash / Share
$5.18
Financials
Financial Snapshot
Market Cap
$207.00B
Enterprise Value
$226.79B
Revenue (TTM)
$30.99B
Net Income (TTM)
-$3.86B
Cash & Investments
$6.44B
Net Cash
-$19.79B
Free Cash Flow (TTM)
$14.04B
Operating CF (TTM)
$14.48B
Debt/Equity
2.01
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $11.89B | $25.51B | $30.09B | $24.35B | $7.41B | $6.52B | $6.38B | $7.26B | $11.57B | $9.61B | $6.44B | |
| Operating Cash Flow | $17.05B | $11.90B | $8.40B | $9.14B | $8.17B | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B | $14.48B | |
| Free Cash Flow | $16.30B | $11.31B | $7.48B | $8.32B | $7.52B | $10.80B | $8.34B | $7.42B | $10.30B | $9.46B | $14.04B | |
| Capital Expenditure | -$748.0M | -$590.0M | -$924.0M | -$825.0M | -$650.0M | -$579.0M | -$728.0M | -$585.0M | -$523.0M | -$563.0M | -$442.0M | |
| Financing Cash Flow | -$9.72B | $3.39B | -$12.32B | -$7.63B | $770.0M | -$8.88B | -$6.47B | -$5.13B | -$3.43B | -$7.75B | -$4.69B |
R&D Spending
R&D (TTM)
$6.33B
R&D Intensity
20.4%
R&D Growth vs Prior
+9.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.39B | $26.11B | $22.13B | $22.45B | $24.69B | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B | $30.99B | |
| R&D Expense | $5.10B | $3.73B | $3.92B | $4.05B | $5.04B | $4.60B | $4.98B | $5.72B | $5.91B | $5.80B | $6.33B | |
| R&D % of Revenue | 16.8% | 14.3% | 17.7% | 18.1% | 20.4% | 16.9% | 18.2% | 21.1% | 20.5% | 19.7% | 20.4% | |
| SG&A | $3.40B | $3.88B | $4.06B | $4.38B | $5.11B | $5.25B | $5.67B | $6.09B | $6.09B | $5.71B | $6.74B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.39B | $26.11B | $22.13B | $22.45B | $24.69B | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B | $30.99B | |
| Cost of Revenue | $4.26B | $4.37B | $4.85B | $4.67B | $4.57B | $6.60B | $5.66B | $6.50B | $6.25B | $6.23B | $6.22B | |
| Gross Profit | $26.13B | $21.74B | $17.27B | $17.77B | $20.12B | $20.70B | $21.62B | $20.62B | $22.50B | $23.21B | $24.77B | |
| R&D | $5.10B | $3.73B | $3.92B | $4.05B | $5.04B | $4.60B | $4.98B | $5.72B | $5.91B | $5.80B | $6.33B | |
| SG&A | $3.40B | $3.88B | $4.06B | $4.38B | $5.11B | $5.25B | $5.67B | $6.09B | $6.09B | $5.71B | $6.74B | |
| Operating Income | $17.63B | $14.12B | $8.20B | $4.29B | $4.07B | $9.92B | $7.33B | $7.61B | $1.66B | $11.70B | -$1.36B | |
| Interest Expense | $964.0M | $1.12B | $1.08B | $995.0M | $984.0M | $1.00B | $935.0M | $944.0M | $977.0M | $1.02B | $1.01B | |
| Pretax Income | $17.10B | $13.53B | $7.80B | $5.16B | $1.67B | $8.28B | $5.81B | $6.86B | $690.0M | $9.80B | -$2.53B | |
| Net Income | $13.50B | $4.63B | $5.46B | $5.39B | $123.0M | $6.22B | $4.59B | $5.67B | $480.0M | $8.51B | -$3.86B | |
| EPS (Diluted) | 9.94 | 3.51 | 4.17 | 4.22 | 0.10 | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 | -3.16 | |
| EBITDA | $19.22B | $15.93B | $10.30B | $7.56B | $4.13B | $11.33B | $8.85B | $10.50B | $4.43B | $13.58B | $823.0M | |
| Shares Out. (M) | 1358.00 | 1319.00 | 1308.00 | 1277.00 | 1263.00 | 1262.00 | 1262.00 | 1258.00 | 1255.00 | 1255.00 | 1251.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.23B | $7.59B | $17.94B | $11.63B | $6.00B | $5.34B | $5.41B | $6.08B | $9.99B | $7.56B | $6.44B | |
| Short-Term Investments | $3.67B | $17.92B | $12.15B | $12.72B | $1.41B | $1.18B | $973.0M | $1.18B | $1.58B | $2.05B | $0.00 | |
| Total Current Assets | $19.59B | $31.82B | $35.84B | $30.30B | $16.00B | $14.77B | $14.44B | $16.09B | $19.17B | $18.34B | $16.55B | |
| Total Assets | $56.98B | $70.28B | $63.67B | $61.63B | $68.41B | $67.95B | $63.17B | $62.13B | $58.99B | $59.02B | $51.41B | |
| Total Current Liabilities | $9.22B | $11.63B | $10.61B | $9.76B | $11.40B | $11.61B | $11.24B | $11.28B | $12.00B | $11.81B | $12.00B | |
| Long-Term Debt | $26.35B | $30.80B | $24.57B | $22.09B | $28.64B | $25.18B | $22.96B | $23.19B | $24.90B | $22.13B | $23.82B | |
| Total Liabilities | $37.61B | $49.78B | $42.14B | $38.98B | $50.19B | $46.89B | $41.96B | $39.38B | $39.75B | $36.41B | $38.45B | |
| Stockholders' Equity | $18.89B | $20.44B | $21.39B | $22.52B | $18.20B | $21.07B | $21.24B | $22.83B | $19.33B | $22.70B | $13.04B | |
| Retained Earnings | $18.15B | $19.01B | $19.02B | $19.39B | $14.38B | $16.32B | $15.69B | $16.30B | $11.50B | $13.73B | $3.11B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $17.05B | $11.90B | $8.40B | $9.14B | $8.17B | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B | $14.48B | |
| Capital Expenditure | -$748.0M | -$590.0M | -$924.0M | -$825.0M | -$650.0M | -$579.0M | -$728.0M | -$585.0M | -$523.0M | -$563.0M | -$442.0M | |
| Free Cash Flow | $16.30B | $11.31B | $7.48B | $8.32B | $7.52B | $10.80B | $8.34B | $7.42B | $10.30B | $9.46B | $14.04B | |
| Investing Cash Flow | -$11.98B | -$16.07B | $14.36B | -$7.82B | -$14.62B | -$3.13B | -$2.47B | -$2.27B | -$3.45B | -$4.79B | -$10.65B | |
| Financing Cash Flow | -$9.72B | $3.39B | -$12.32B | -$7.63B | $770.0M | -$8.88B | -$6.47B | -$5.13B | -$3.43B | -$7.75B | -$4.69B | |
| Issuance of Stock | $208.0M | $234.0M | $289.0M | $209.0M | $256.0M | $169.0M | $309.0M | $232.0M | $422.0M | $408.0M | $294.0M | |
| Repurchase of Stock | -$11.00B | -$954.0M | -$2.90B | -$1.75B | -$1.58B | -$546.0M | -$1.40B | -$1.00B | -$1.15B | -$1.92B | -$1.37B | |
| Net Debt Issuance | $4.27B | $7.17B | -$6.25B | -$2.75B | $5.68B | -$4.75B | -$1.50B | -$270.0M | $1.49B | -$1.79B | $1.27B | |
| Stock Based Comp. | $380.0M | $638.0M | $845.0M | $636.0M | $643.0M | $635.0M | $644.0M | $766.0M | $835.0M | $894.0M | $464.0M | |
| Net Change in Cash | -$4.62B | -$641.0M | $10.35B | -$6.31B | -$5.63B | -$659.0M | $74.0M | $673.0M | $3.91B | -$2.43B | -$890.0M |
Dilution Tracker
Shares Outstanding
1240M
5-Year Share Growth
-0.6%
Stock Issuance (TTM)
$294.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1358.00 | 1319.00 | 1308.00 | 1277.00 | 1263.00 | 1262.00 | 1262.00 | 1258.00 | 1255.00 | 1255.00 | 1251.00 | |
| Change vs Prior % | — | -2.9% | -0.8% | -2.4% | -1.1% | -0.1% | 0.0% | -0.3% | -0.2% | 0.0% | -0.3% | |
| Stock Issuance | $208.0M | $234.0M | $289.0M | $209.0M | $256.0M | $169.0M | $309.0M | $232.0M | $422.0M | $408.0M | $294.0M | |
| Stock Repurchase | -$11.00B | -$954.0M | -$2.90B | -$1.75B | -$1.58B | -$546.0M | -$1.40B | -$1.00B | -$1.15B | -$1.92B | -$1.37B | |
| Stock Based Comp. | $380.0M | $638.0M | $845.0M | $636.0M | $643.0M | $635.0M | $644.0M | $766.0M | $835.0M | $894.0M | $464.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 86.0% | 83.3% | 78.1% | 79.2% | 81.5% | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% | 79.9% | |
| Operating Margin % | 58.0% | 54.1% | 37.1% | 19.1% | 16.5% | 36.3% | 26.9% | 28.0% | 5.8% | 39.7% | -4.4% | |
| Net Margin % | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% | -12.5% | |
| EBITDA Margin % | 63.2% | 61.0% | 46.6% | 33.7% | 16.7% | 41.5% | 32.4% | 38.7% | 15.4% | 46.1% | 2.7% | |
| FCF Margin % | 53.6% | 43.3% | 33.8% | 37.1% | 30.5% | 39.6% | 30.6% | 27.4% | 35.8% | 32.1% | 45.3% | |
| ROE % | 71.5% | 22.6% | 25.5% | 23.9% | 0.7% | 29.5% | 21.6% | 24.8% | 2.5% | 37.5% | -21.7% | |
| ROA % | 23.7% | 6.6% | 8.6% | 8.7% | 0.2% | 9.2% | 7.3% | 9.1% | 0.8% | 14.4% | -7.5% | |
| ROIC % | 29.1% | 7.9% | 10.3% | 7.9% | 0.4% | 12.8% | 10.6% | 11.8% | 2.4% | 20.3% | -3.2% | |
| R&D / Revenue % | 16.8% | 14.3% | 17.7% | 18.1% | 20.4% | 16.9% | 18.2% | 21.1% | 20.5% | 19.7% | 20.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -6.9% | -14.1% | -15.2% | 1.5% | 10.0% | 10.6% | -0.1% | -0.6% | 6.0% | 2.4% | |
| Gross Profit | -8.7% | -16.8% | -20.5% | 2.9% | 13.2% | 2.9% | 4.4% | -4.7% | 9.1% | 3.1% | |
| Operating Income | -20.5% | -19.9% | -41.9% | -47.7% | -5.0% | 143.6% | -26.1% | 3.8% | -78.1% | 604.0% | |
| Net Income | -25.4% | -65.7% | 17.9% | -1.3% | -97.7% | 4961.0% | -26.2% | 23.4% | -91.5% | 1672.9% | |
| EPS (Diluted) | -16.5% | -64.7% | 18.8% | 1.2% | -97.7% | 4961.6% | -26.2% | 23.6% | -91.6% | 1684.2% | |
| Operating Cash Flow | -19.8% | -30.2% | -29.4% | 8.9% | -10.7% | 39.4% | -20.3% | -11.8% | 35.2% | -7.5% | |
| Free Cash Flow | -20.5% | -30.6% | -33.9% | 11.3% | -9.6% | 43.7% | -22.8% | -11.1% | 38.9% | -8.2% | |
| R&D Expense | 69.1% | -26.8% | 5.0% | 3.4% | 24.3% | -8.7% | 8.2% | 14.9% | 3.3% | -1.8% | |
| SG&A Expense | -0.8% | 14.1% | 4.6% | 8.0% | 16.7% | 2.6% | 8.1% | 7.4% | 0.0% | -6.3% | |
| Total Assets | 10.2% | 23.4% | -9.4% | -3.2% | 11.0% | -0.7% | -7.0% | -1.7% | -5.0% | 0.0% | |
| Book Value / Share | 10.8% | 8.5% | 5.8% | 7.5% | -18.7% | 15.7% | 0.8% | 7.9% | -15.3% | 17.8% | |
| Debt | 19.5% | 27.3% | -18.5% | -10.0% | 27.7% | -15.0% | -5.5% | -1.0% | 6.9% | -6.6% | |
| Diluted Shares | -10.7% | -2.9% | -0.8% | -2.4% | -1.1% | -0.1% | 0.0% | -0.3% | -0.2% | 0.0% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High7.10 / 17.94 / 595.10
P/S6.68
10Y Low / Med / High2.97 / 3.68 / 5.19
P/B15.90
10Y Low / Med / High3.66 / 4.58 / 6.73
EV/EBITDA275.57
10Y Low / Med / High5.93 / 12.52 / 29.75
EV/Revenue7.32
10Y Low / Med / High3.75 / 4.43 / 5.78
P/FCF14.75
10Y Low / Med / High5.88 / 10.86 / 16.15
Intrinsic Value Models (per share)
DCF Value
$137.19
Cash / Share
$5.18
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 7.10 | 20.24 | 14.89 | 15.33 | 595.10 | 14.64 | 23.46 | 17.84 | 243.08 | 17.94 | -53.84 | |
| P/S Ratio | 3.16 | 3.59 | 3.67 | 3.68 | 2.97 | 3.34 | 3.95 | 3.73 | 4.01 | 5.19 | 6.68 | |
| P/B Ratio | 5.08 | 4.58 | 3.80 | 3.66 | 4.02 | 4.33 | 5.07 | 4.43 | 5.96 | 6.73 | 15.90 | |
| EV/EBITDA | 5.93 | 7.51 | 8.79 | 12.63 | 23.87 | 9.94 | 14.41 | 11.43 | 29.75 | 12.52 | 275.57 | |
| EV/Revenue | 3.75 | 4.58 | 4.09 | 4.25 | 4.00 | 4.12 | 4.68 | 4.43 | 4.59 | 5.78 | 7.32 |
Analyst Estimates & Quality
Altman Z-Score
3.90
Safe
Piotroski F-Score
5
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $31.27B | $33.49B | $34.78B |
| Net Income | -$1.25B | $12.67B | $13.45B |
| EPS | $-0.85 | $10.10 | $10.78 |
| # Analysts (EPS) | 14 | 16 | 10 |
Dividends
Dividend/Share (TTM)
$3.25
Dividend Yield
1.95%
Frequency
Quarterly
Next Payment
Dec 30, 2026
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Dec 15, 2026 | Dec 30, 2026 | $0.82 | Quarterly |
| Sep 15, 2026 | Sep 29, 2026 | $0.82 | Quarterly |
| Jun 15, 2026 | Jun 29, 2026 | $0.82 | Quarterly |
| Mar 13, 2026 | Mar 30, 2026 | $0.82 | Quarterly |
| Dec 15, 2025 | Dec 30, 2025 | $0.79 | Quarterly |
| Sep 15, 2025 | Sep 29, 2025 | $0.79 | Quarterly |
| Jun 13, 2025 | Jun 27, 2025 | $0.79 | Quarterly |
| Mar 14, 2025 | Mar 28, 2025 | $0.79 | Quarterly |
| Dec 13, 2024 | Dec 30, 2024 | $0.77 | Quarterly |
| Sep 13, 2024 | Sep 27, 2024 | $0.77 | Quarterly |
| Jun 14, 2024 | Jun 27, 2024 | $0.77 | Quarterly |
| Mar 14, 2024 | Mar 28, 2024 | $0.77 | Quarterly |
| Dec 14, 2023 | Dec 28, 2023 | $0.75 | Quarterly |
| Sep 14, 2023 | Sep 28, 2023 | $0.75 | Quarterly |
| Jun 14, 2023 | Jun 29, 2023 | $0.75 | Quarterly |
| Mar 14, 2023 | Mar 30, 2023 | $0.75 | Quarterly |
| Dec 14, 2022 | Dec 29, 2022 | $0.73 | Quarterly |
| Sep 14, 2022 | Sep 29, 2022 | $0.73 | Quarterly |
| Jun 14, 2022 | Jun 29, 2022 | $0.73 | Quarterly |
| Mar 14, 2022 | Mar 30, 2022 | $0.73 | Quarterly |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cell Therapy Products, Total Cell Therapy Product Sales | $607.0M | $1.05B | $1.76B | $2.24B | $2.38B | — |
| Other Products, Total Other product sales | $1.89B | $1.03B | $946.0M | $859.0M | $889.0M | — |
| Products, Other HIV | $17.00B | $16.36B | $17.25B | $18.23B | $19.61B | — |
| Hepatitis B Virus / Hepatitis Delta Virus Product | — | $969.0M | $988.0M | $1.02B | — | — |
| Trodelvy | — | $380.0M | $680.0M | $1.06B | $1.31B | $1.40B |
| Veklury | — | $5.57B | $3.90B | $2.18B | $1.80B | $911.0M |
| Biktarvy | — | — | — | — | — | $14.33B |
| Descovy | — | — | — | — | — | $2.76B |
| Genvoya | — | — | — | — | — | $1.50B |
| Odefsey | — | — | — | — | — | $1.17B |
| Symtuza - Revenue share | — | — | — | — | — | $495.0M |
| Other HIV | — | — | — | — | — | $500.0M |
| Tecartus | — | — | — | — | — | $344.0M |
| Yescarta | — | — | — | — | — | $1.50B |
| Sofosbuvir/Velpatasvir | — | — | — | — | — | $1.27B |
| Vemlidy | — | — | — | — | — | $1.07B |
| Other Liver Disease | — | — | — | — | — | $874.0M |
| AmBisome | — | — | — | — | — | $509.0M |
| Other | — | — | — | — | — | $290.0M |
| Royalty, contract and other revenues | — | — | — | — | — | $527.0M |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Europe | $4.13B | $4.87B | $4.47B | $4.31B | $4.63B | $5.06B |
| Other International | $2.34B | $3.16B | $3.93B | $3.37B | $3.53B | $3.50B |
| UNITED STATES | $18.22B | $19.27B | $18.88B | $19.44B | $20.59B | $20.88B |